Last reviewed · How we verify
NCT05689801: EHDXTRQV
Describe the Effect of the Optimized Hemodialysis Technique (HDx) With Medium Cut-Off Membrane on Recovery Time and Quality of Life
NA trial testing Questionnaire "recovery time after a dialysis session". in Terminal Renal Insufficiency in 20 participants. Status unknown.
15 June 2023
Quick facts
| Lead sponsor | Ramsay Générale de Santé |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 20 |
| Start date | 15 December 2022 |
| Primary completion | 15 June 2023 |
| Estimated completion | 15 January 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- Questionnaire "recovery time after a dialysis session".
- SF-12 questionnaire
- EQ-5D-5L Questionnaire
- Pittman, John et McIntyre questionnaire
- Conventional hemodialysis
- Optimized hemodialysis
Conditions studied
- Terminal Renal Insufficiency — all drugs for Terminal Renal Insufficiency →
Sponsor
Ramsay Générale de Santé — full company profile →
Who can join
18 and older, any sex, with Terminal Renal Insufficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the effect of optimizing the dialytic technique using simple questionnaires carried out in clinical routine will be described. More specifically, the conventional dialysis technique will be combined with biofeedback software called HemoControl™. The recovery time and quality of life of patients who will use a polyethersulfone membrane (Revaclear®) and a Medium Cut-Off (MCO) membrane (Theranova®) will be observed. The main objective is to describe the evolution of recovery time after a dialysis session in conventional hemodialysis (HD) on Revaclear® membrane and in so-called optimized hemodialysis (HDx) on MCO membrane, Theranova®.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05689801
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Ramsay Générale de Santé trials
Trials by the same sponsor.
- NCT07353060 — Prognostic Profile of Dupuytren's Disease: a Cohort Study (PRODUCT) · NA · not yet recruiting
- NCT07245823 — Randomized Study Evaluating the Treatment of Vulvovaginal Gaping by Plication of the Puborectalis Muscles Versus Perineo · NA · recruiting
- NCT07142330 — Evaluation of Atherectomy in the Management of Occlusive Lesions of the Common Femoral Arteries · not yet recruiting
- NCT07203131 — Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Ca · NA · recruiting
- NCT07469007 — Impact of Surgery for Deep Posterior Endometriosis on Ovarian Reserve (ENDORO) · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05689801 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ramsay Générale de Santé
- Last refreshed: 19 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05689801.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing